Kiranj Chaudagar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kiranj Chaudagar has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Akash Patnaik
University of Chicago, Chicago, IL
93 shared publications - Srikrishnan Rameshbabu
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
89 shared publications - Sweta Sharma Saha
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Newcastle upon Tyne UK
70 shared publications - Alison Thomas
Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
69 shared publications - Brian M. Olson
Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
69 shared publications - Christina Hong
Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
69 shared publications
Latest Publications
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF18
Spatial Statistics Infer Structured Immune Signatures in Primary Prostate Cancer
The spatial arrangement of immune cells in the tumor microenvironment (TME) varies widely, from dispersed to clustered and tumor-excluded to infiltrating. Multiplexed spatial profiling is an effective means of characterizing tumor-infiltrating lymphocytes and immune complexes such as tertiary lymphoid structures (TLS) in the TME. However, few approaches have been described for objectively parametrizing patterns of immune organization and assessing their association with biological or clinical variables. This makes it difficult to evaluate whether a set of tumors is relatively immunologically cold or hot. In this study, we describe an intuitive set of statistical tools (available in the R package, tlsR) for characterizing lymphocyte patterns in the TME of solid cancers. We applied tlsR to primary prostate cancer, which is often described as immunologically “cold.” Using a cohort of 29 radical prostatectomy specimens stratified into low Gleason grade (LGG; n = 15) and high Gleason grade (HGG; n = 14), we showed that HGG prostate cancer is significantly more infiltrated than LGG prostate cancer, with lymphocytes organized into B or T cell–enriched immune clusters (IC). A subset of these ICs had the B- and T-cell zonation and follicular dendritic cells characteristic of bona fide TLSs. HGGs were also enriched with ICs containing precursors of exhausted T cells and proliferating B cells, and their tumor compartments harbored granzyme B+ cytotoxic T cells in contact with cancer cells. Thus, far from being cold, a subset of HGG prostate cancer has features associated with active immune surveillance, a finding with implications for emerging prostate cancer immunotherapies.
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF18
Spatial Statistics Infer Structured Immune Signatures in Primary Prostate Cancer
The spatial arrangement of immune cells in the tumor microenvironment (TME) varies widely, from dispersed to clustered and tumor-excluded to infiltrating. Multiplexed spatial profiling is an effective means of characterizing tumor-infiltrating lymphocytes and immune complexes such as tertiary lymphoid structures (TLS) in the TME. However, few approaches have been described for objectively parametrizing patterns of immune organization and assessing their association with biological or clinical variables. This makes it difficult to evaluate whether a set of tumors is relatively immunologically cold or hot. In this study, we describe an intuitive set of statistical tools (available in the R package, tlsR) for characterizing lymphocyte patterns in the TME of solid cancers. We applied tlsR to primary prostate cancer, which is often described as immunologically “cold.” Using a cohort of 29 radical prostatectomy specimens stratified into low Gleason grade (LGG; n = 15) and high Gleason grade (HGG; n = 14), we showed that HGG prostate cancer is significantly more infiltrated than LGG prostate cancer, with lymphocytes organized into B or T cell–enriched immune clusters (IC). A subset of these ICs had the B- and T-cell zonation and follicular dendritic cells characteristic of bona fide TLSs. HGGs were also enriched with ICs containing precursors of exhausted T cells and proliferating B cells, and their tumor compartments harbored granzyme B+ cytotoxic T cells in contact with cancer cells. Thus, far from being cold, a subset of HGG prostate cancer has features associated with active immune surveillance, a finding with implications for emerging prostate cancer immunotherapies.
- Open Access
Immune determinants of leuprolide-associated cardiovascular risk in prostate cancer
Background and hypothesis: Leuprolide, the most widely used gonadotropin-releasing hormone receptor (GnRHR) agonist for androgen deprivation therapy (ADT) in prostate cancer (PC), is associated with increased risk of cardiovascular events (CVE), but the underlying mechanisms remain poorly defined. Given the pivotal contribution of circulatory immune components to cardiovascular complications, we hypothesized that leuprolide alters the cardiac immune microenvironment and that pre-existing circulating immune phenotypes determine the patient vulnerability to CVE. Methods: We integrated spatial transcriptomics of coronary plaque and cardiac tissues from leuprolide-treated mice, with longitudinal immune profiling blood leukocytes of PC patients receiving leuprolide. Spatial analyses examined treatment-associated changes in cellular composition, inferred receptor signaling, transcriptional programs and intercellular communication across coronary plaque and non-plaque cardiac compartments. Peripheral blood from 25 patients was profiled longitudinally by multiparametric flow cytometry together with measurement of circulating adipocytokines. Results: Leuprolide selectively reorganized the coronary plaque microenvironment in mice, characterized by altered GnRHR- and androgen receptor-signaling in plaque fibroblasts, organization of T+B lymphoid aggregates, and enrichment of inflammatory M1-like macrophages exhibiting interferon and mesenchymal-remodeling programs. These changes accompanied by non-plaque alteration, particularly ventricular cardiomyocyte hypertrophy in murine heart. Approximately ∼44% of PC patients receiving leuprolide had CD8 + T cell phenotype that associated with treatment-related CVE, including ventricular dysfunctions. A composite signature incorporating Tc1 (type 1 cytotoxic T cells), CD8 + effector-memory, CD8 + transitional-memory and CD8 lo T cell populations distinguished this susceptible phenotype. Conclusions: These findings establish cardiovascular immune remodeling as a framework for leuprolide-associated CVE and nominate pre-existing circulating CD8 + T cell states as candidate biomarkers for prospective ADT-risk stratification. Novelty and Significance: The mechanisms underlying cardiovascular complications of GnRH receptor agonist therapy remain incompletely understood. We combined spatial transcriptomic analysis of coronary plaque and cardiac tissue with longitudinal immune profiling of patients with prostate cancer receiving leuprolide. Leuprolide was associated with a plaque-specific immune responses, involving altered fibroblast GnRH-signaling, increased T+B lymphoid aggregates, and inflammatory M1-like macrophages with interferon and mesenchymal-remodeling programs. In contrast, histologically normal vasculature showed a predominantly M2-like macrophage response. Changes outside the plaque included adipose-stromal remodeling and an increase in hypertrophic ventricular cardiomyocytes. In patients, a pre-existing CD8 + T cells had phenotype associated with treatment-related cardiovascular events, including ventricular dysfunction. A signature comprising Tc1, CD8 + effector-memory, CD8 + transitional-memory, and CD8 lo T cell populations distinguished this immune phenotype. These observations suggest that the cardiovascular response to leuprolide is influenced by both the local tissue environment and the pre-existing systemic immune state. The circulating T-cell signature warrants prospective validation as a potential approach to identify patients who may be more susceptible to cardiovascular complications during androgen deprivation therapy.
Open AccessImmune determinants of leuprolide-associated cardiovascular risk in prostate cancer
Background and hypothesis: Leuprolide, the most widely used gonadotropin-releasing hormone receptor (GnRHR) agonist for androgen deprivation therapy (ADT) in prostate cancer (PC), is associated with increased risk of cardiovascular events (CVE), but the underlying mechanisms remain poorly defined. Given the pivotal contribution of circulatory immune components to cardiovascular complications, we hypothesized that leuprolide alters the cardiac immune microenvironment and that pre-existing circulating immune phenotypes determine the patient vulnerability to CVE. Methods: We integrated spatial transcriptomics of coronary plaque and cardiac tissues from leuprolide-treated mice, with longitudinal immune profiling blood leukocytes of PC patients receiving leuprolide. Spatial analyses examined treatment-associated changes in cellular composition, inferred receptor signaling, transcriptional programs and intercellular communication across coronary plaque and non-plaque cardiac compartments. Peripheral blood from 25 patients was profiled longitudinally by multiparametric flow cytometry together with measurement of circulating adipocytokines. Results: Leuprolide selectively reorganized the coronary plaque microenvironment in mice, characterized by altered GnRHR- and androgen receptor-signaling in plaque fibroblasts, organization of T+B lymphoid aggregates, and enrichment of inflammatory M1-like macrophages exhibiting interferon and mesenchymal-remodeling programs. These changes accompanied by non-plaque alteration, particularly ventricular cardiomyocyte hypertrophy in murine heart. Approximately ∼44% of PC patients receiving leuprolide had CD8 + T cell phenotype that associated with treatment-related CVE, including ventricular dysfunctions. A composite signature incorporating Tc1 (type 1 cytotoxic T cells), CD8 + effector-memory, CD8 + transitional-memory and CD8 lo T cell populations distinguished this susceptible phenotype. Conclusions: These findings establish cardiovascular immune remodeling as a framework for leuprolide-associated CVE and nominate pre-existing circulating CD8 + T cell states as candidate biomarkers for prospective ADT-risk stratification. Novelty and Significance: The mechanisms underlying cardiovascular complications of GnRH receptor agonist therapy remain incompletely understood. We combined spatial transcriptomic analysis of coronary plaque and cardiac tissue with longitudinal immune profiling of patients with prostate cancer receiving leuprolide. Leuprolide was associated with a plaque-specific immune responses, involving altered fibroblast GnRH-signaling, increased T+B lymphoid aggregates, and inflammatory M1-like macrophages with interferon and mesenchymal-remodeling programs. In contrast, histologically normal vasculature showed a predominantly M2-like macrophage response. Changes outside the plaque included adipose-stromal remodeling and an increase in hypertrophic ventricular cardiomyocytes. In patients, a pre-existing CD8 + T cells had phenotype associated with treatment-related cardiovascular events, including ventricular dysfunction. A signature comprising Tc1, CD8 + effector-memory, CD8 + transitional-memory, and CD8 lo T cell populations distinguished this immune phenotype. These observations suggest that the cardiovascular response to leuprolide is influenced by both the local tissue environment and the pre-existing systemic immune state. The circulating T-cell signature warrants prospective validation as a potential approach to identify patients who may be more susceptible to cardiovascular complications during androgen deprivation therapy.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Androgen deprivation increases the frequency of infiltrating T cells and M1 tumor-associated macrophages in the tumor microenvironment.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Androgen deprivation increases the frequency of infiltrating T cells and M1 tumor-associated macrophages in the tumor microenvironment.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Decreased Rb1 expression correlates with predicted decreased immune infiltration across multiple disease histologies.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Decreased Rb1 expression correlates with predicted decreased immune infiltration across multiple disease histologies.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Pharmacological inhibition of BET family members by JQ-1.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Pharmacological inhibition of BET family members by JQ-1.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
List of antibodies used in experiments
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
List of antibodies used in experiments
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Generation and characterization of growth kinetics of Rb-deficient Myc-CaP cell line.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Generation and characterization of growth kinetics of Rb-deficient Myc-CaP cell line.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
JQ-1 treatment in vivo increases PD-L1 expression on myeloid suppressive cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
JQ-1 treatment in vivo increases PD-L1 expression on myeloid suppressive cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
T cell and macrophage depletion studies in mice bearing Myc-CaPWT or Myc-CaPΔRb tumors.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
T cell and macrophage depletion studies in mice bearing Myc-CaPWT or Myc-CaPΔRb tumors.